Morinaga Milk Achieves Self-Affirmed GRAS Status for LAC-Living+™, Expanding U.S. Opportunities for Its Postbiotic Ingredient
7.7.2026 05:00:00 EEST |Business Wire |Press release
Share
Morinaga Milk Industry Co., Ltd. (TOKYO:2264), a leading Japanese dairy and functional ingredient company, today announced that it has achieved self-affirmed GRAS (Generally Recognized As Safe) status in the United States for LAC-Living+™ (L. helveticusMCC1848), its proprietary postbiotic ingredient. This milestone expands the commercial availability of LAC-Living+ in the U.S. market and enables its use in dietary supplements, functional foods, and beverages, supporting the development of products designed to address growing consumer demand for health and well-being solutions.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706806943/en/
Growing Interest in Postbiotics and Mental Well-Being
Consumer interest in proactive health management has expanded significantly in recent years, alongside increasing awareness of the connection between the gut and the brain, commonly referred to as the gut–brain axis. As a result, the global functional ingredient market is evolving beyond conventional probiotics to include postbiotics—non-viable microorganisms and/or their components that offer physiological benefits. Postbiotics are gaining attention due to their stability, safety, and ease of formulation, particularly in product formats that are challenging for live microorganisms. These advantages make them an attractive option for manufacturers seeking reliable, science-based ingredients.
Morinaga Milk has been at the forefront of postbiotic research and development. In 2018, the company achieved self-affirmed GRAS status for LAC-Shield™ (L. paracasei MCC1849), its first postbiotic ingredient. Building on this experience, LAC-Living+™ represents the company’s second postbiotic innovation, developed to address emerging consumer needs in the area of mood and mental well-being
LAC-Living+™: Clinical Evidence Supporting Everyday Well-Being
LAC-Living+™ (L. helveticus MCC1848) is a heat-treated postbiotic ingredient developed to combine scientific credibility with formulation flexibility. Its functionality has been evaluated in human clinical studies, which suggest that supplementation with LAC-Living+ may help support mental well-being and quality of life, particularly in individuals experiencing everyday stress. Reported outcomes have included improvements in indicators related to mood and psychological state, providing a scientific basis for its application in products targeting mental wellness. In Japan, L. helveticus MCC1848 has also been accepted as a functional ingredient under the Foods with Function Claims (FFC) system, with reported functionality to help maintain a positive mood (vitality) in situations involving temporary mental stress. While research into the gut–brain axis continues to evolve, such findings and achievements are contributing to a growing body of evidence supporting the role of microbiome-related ingredients in holistic health approaches that integrate physical and mental well-being.
Formulation Advantages for Broad Applications
In addition to its scientific foundation, LAC-Living+™ offers important technical advantages for product development
As a postbiotic ingredient, LAC-Living+™ is non-viable, which allows it to maintain stability under conditions that may compromise live microorganisms. This includes exposure to heat processing, moisture, and extended shelf-life environments, making it suitable for a wide variety of applications. These characteristics provide manufacturers with greater flexibility in formulation and product design, supporting its use across categories such as ready-to-drink beverages, powders, bars, gummies, dairy products, and supplements.
Supporting Innovation in the U.S. Market
The attainment of self-affirmed GRAS status represents a key step in enabling broader adoption of LAC-Living+™ in the United States
“Achieving self-affirmed GRAS status for LAC-Living+™ marks an important milestone for our postbiotic portfolio,” said Masashi Kamiya, General Manager of Functional Food Ingredients Division at Morinaga Milk Industry Co., Ltd. “With increasing interest in mental well-being and convenient health solutions, we believe LAC-Living+™ offers strong potential to support our partners in developing innovative products tailored to evolving consumer needs.”
Morinaga Milk remains committed to advancing its research and ingredient development efforts, with a focus on delivering safe, scientifically supported, and application-friendly solutions to the global market
About Morinaga Milk Industry Co., Ltd
Morinaga Milk Industry Co., Ltd. is one of Japan’s leading dairy companies, with more than 100 years of experience in harnessing the nutritional value of dairy and functional ingredients
The company is recognized globally for its expertise in probiotics, postbiotics, and microbiome-related research, supported by decades of scientific investigation into the safety, functionality, and mechanisms of action of beneficial microorganisms. Since the 1960s, Morinaga Milk has been advancing research into bifidobacteria and their role in human health, contributing to the development of high-quality, science-based solutions for a wide range of applications.
For more information about Morinaga probiotics and postbiotics, please visit: https://morinagamilk-ingredients.com/
View ws/home/20260706806943/en/
Contacts
Morinaga Milk Industry Co., Ltd.Investor& Public Relations Department: Kazuaki KajikawaFunctional Food Ingredients Division: Saki YamashitaE-mail:interntl-pr@morinagamilk.co.jpMorinaga Milk website: https://www.morinagamilk.co.jp/english/ -https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.morinagamilk.co.jp%2Fenglish%2F&esheet=54565568&newsitemid=20260706806943&lan=en-US&anchor=https%3A%2F%2Fwww.morinagamilk.co.jp%2Fenglish%2F&index=2&md5=99286906205e029efa334bb310456c04
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure
www.businesswire.com
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time
Latest releases from Business Wire
Loomis Sayles Growth Equity Strategies Team Celebrates Twenty-Year Milestones7.7.2026 17:36:00 EEST | Press release
Loomis, Sayles & Company, the century-old investment manager with nearly $418 billion in assets under management, proudly celebrates the 20-year anniversaries of the Loomis Sayles Large Cap Growth and the Loomis Sayles All Cap Growth strategies, as well as a differentiated approach to growth equity investing under the leadership of Aziz V. Hamzaogullari, CFA, the founder, chief investment officer and portfolio manager of the Loomis Sayles Growth Equity Strategies (GES) Team. Aziz is also an executive vice president and a member of the firm’s Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260707992418/en/ Celebrating 20 Years of The Power of Active Management Done Right GES is a cohesive team with 20 years of alpha generation and a long-term, private equity approach to investing. Under Aziz Hamzaogullari’s leadership since 2010, assets under management for GES have grown from $1.9 billion to $98.2 billion
Integral Ad Science Appoints Lidiane Jones Chief Executive Officer7.7.2026 16:35:00 EEST | Press release
Integral Ad Science (IAS), one of the world’s most trusted media quality companies, today announced the appointment of Lidiane Jones as Chief Executive Officer, effective immediately. Jones succeeds Lisa Utzschneider, who led IAS for more than seven years and will remain with the company as Special Advisor to the Board through the end of 2026 to support a seamless transition. Utzschneider will also serve as a Special Advisor to Novacap and their portfolio companies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260707780892/en/ Lidiane Jones: Integral Ad Science CEO, Photo Credit: Pamela Hanson The appointment reflects IAS’s long-term strategic vision for the future of digital advertising. As AI transforms how media is planned, bought, measured, and optimized, advertisers increasingly need trusted intelligence to make real-time decisions. Jones’s deep expertise across product, technology, and AI uniquely positions IAS to bu
Andersen Global Adds Collaborating Firm Abcoo Law Firm7.7.2026 16:30:00 EEST | Press release
Andersen Global strengthens its presence in Türkiye with collaborating firm Abcoo Law Firm, enhancing the organization’s existing platform in the country with the addition of legal capabilities. Founded in 2014, Abcoo advises local and international clients across a broad range of legal services, with experience in corporate and M&A, real estate and construction, dispute resolution, employment, compliance, banking and finance, competition and intellectual property law. The firm is consistently recognized as a top tier and leading firm by international publications, including The Legal 500. Abcoo supports organizations across a wide range of industries, including real estate and construction, retail, textile, cosmetics, automotive, logistics, chemicals, IT, energy, healthcare, manufacturing and financial services, providing strategic legal guidance and commercially focused solutions. “Our focus has always been on understanding each client’s objectives and providing practical, commercial
Altasciences and Evidence Matters Advance AI-Driven Drug Development With Nonclinical Automation Breakthrough7.7.2026 16:00:00 EEST | Press release
Altasciences, a fully integrated early-phase drug development organization, and Evidence Matters, a pioneer in clinical trial data science, are pleased to announce a successful proof-of-concept (POC) of RegulatoryFlow (“RegFlow”), following the announcement of the companies’ strategic collaboration in August 2025. The POC demonstrated the extension of AI-driven efficiencies from clinical reporting into nonclinical workflows, marking a significant step forward in accelerating drug development timelines. Building on proven results in clinical reporting, where the collaboration has achieved up to first-draft clinical study reports (CSRs), the teams have now successfully applied similar AI capabilities to nonclinical data through high-quality parsing of raw and SEND datasets in a proof-of-concept. This advancement aligns with the Altasciences Acceleration Platform, designed to fast-track drug development across the early-phase development continuum. “This milestone reflects the power of in
Gurobi Launches Intelligence Hub to Deliver AI-Guided Workflows Across the Optimization Lifecycle7.7.2026 16:00:00 EEST | Press release
Gurobi Optimization, LLC, the leader in decision intelligence technology, today announced the launch of the Gurobi Intelligence Hub, the new home for Gurobi’s AI-powered optimization agents. The Intelligence Hub is designed to help users build, understand, troubleshoot, and interact with optimization models more effectively. Together, the Hub’s specialized agents leverage generative AI to guide users through workflows across the optimization lifecycle, creating new opportunities to make optimization more accessible, intuitive, and valuable for a broader range of users. The Modeler combines guided workflows with Gurobi’s optimization expertise to help users move from business problem to production-quality optimization model. Through an iterative process that helps refine requirements, validate assumptions, and develop acceptance tests, the Modeler gives users confidence that their model accurately reflects the intended business problem.The Explainer helps users interpret model instances
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us
Visit our pressroom
